NCT01139723View on ClinicalTrials.gov

A Study of the Safety and Pharmacokinetics of MINT1526A, Administered Intravenously As a Single Agent and in Combination With Bevacizumab to Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions
Solid Cancers
Interventions
DRUG

MINT1526A

Intravenous escalating dose

DRUG

bevacizumab

Intravenous repeating dose

Trial Locations (3)

80045

Aurora

90095

Los Angeles

92008

Encinitas

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY